NAD+

Graded C: NAD+ given directly (mainly by IV infusion) has only small, mostly industry-linked pharmacokinetic and tolerability studies and no efficacy trials; better-studied oral precursors are different products.

Strengths: 500, 1000 mg
Also known as: Nicotinamide adenine dinucleotide, β-NAD, Oxidized form of NADH
Molecule: Dinucleotide coenzyme (vitamin B3 derived; not a peptide)
Formula: C21H27N7O14P2
Mol. weight: 663.43 g/mol
CAS: 53-84-9

Origin

A coenzyme every cell makes, built from two nucleotides joined by a phosphate bridge. The catalog labels it 'Coenzyme (not a peptide).'

How it works

NAD+ carries electrons in the pathways that turn food into energy and is consumed by sirtuins, PARP DNA-repair enzymes and CD38. Animal and cell work shows levels fall with age. Whether NAD+ given from outside the body reaches cells intact is unresolved; in the main human infusion study, breakdown products rose alongside it.

What the research shows

Human research on NAD+ given directly is limited to small pharmacokinetic and tolerability studies: an 11-person infusion study, a company-funded randomized pilot comparing it with nicotinamide riboside, and a 14-person retrospective clinic review. A 2026 systematic review found no controlled outcome trials of IV or injectable NAD+. Oral precursors (NR and NMN) have small trials showing higher blood NAD+ and some metabolic findings, but those are different products. A 2026 study questioned whether blood NAD+ consistently falls with age.

Key studies

Grant et al., Frontiers in Aging Neuroscience 2019 Infusion study in 11 healthy men: plasma NAD+ rose late in the infusion; no adverse events.
Hawkins et al., medRxiv preprint 2024 Company-funded pilot: IV NAD+ caused more infusion symptoms than IV NR and raised white-cell counts.
Reyna et al., Frontiers in Aging 2026 Clinic records: all NAD+ recipients reported moderate-to-severe symptoms that stopped when infusion ended.
Freeberg et al., J Gerontol A 2023 Review: oral NR and NMN raise NAD+ metabolites; functional benefits remain unclear.

Safety findings

Studies report rate-related symptoms during infusion (cramping, nausea, vomiting, faster heart rate, chest pressure) that eased when the infusion was slowed or stopped, and a white-cell rise suggesting a possible inflammatory response. FDA has received reports of severe chills, shaking and vomiting after administration of NAD+ products, attributed to endotoxin from food-grade material, and a Class I recall followed in 2025. Interactions have not been studied.

Regulatory status

There is no FDA-approved NAD+ drug. NAD is in 503A Category 1 (under evaluation) on FDA's May 2026 list, and FDA confirmed NMN is lawful as a dietary supplement in 2025. NAD+ is not named on the 2026 WADA list, though WADA's method rules (M2.2) restrict large-volume IV infusions without an exemption.

Catalog notes

Available in 500 and 1,000 mg, both with certificates tested August 17, 2026: lot NAD500-0803 (99.78%, COA7592) and lot NAD1000-0803 (99.74%, COA7611); no endotoxin or sterility results are listed. Follow the storage stated on the label and certificate. Also offered as a spray and a strip.

In kits: NAD Stack Bundle, Prime Bundle